Phase 3 trial, 187 adults with acute leukaemias or MDS having myeloablative alloHSCT: Orca-T vs tacrolimus/methotrexate improved survival free of moderate-to-severe chronic GVHD (1-year estimate 78.0% vs 38.4%; HR 0.26); overall survival not significantly different.
RCTn = 187
Meyer et al. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial